These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24947255)

  • 21. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
    Johnson BE; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Lin CY; Marsland T; Patel T; Polikoff J; Rubin M; White L; Yang JC; Bowden C; Miller V
    J Clin Oncol; 2013 Nov; 31(31):3926-34. PubMed ID: 24101054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
    de Gramont A; Van Cutsem E
    Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
    Mitchell EP
    Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current status of antiangiogenic therapies for glioblastomas.
    Arrillaga-Romany I; Reardon DA; Wen PY
    Expert Opin Investig Drugs; 2014 Feb; 23(2):199-210. PubMed ID: 24320142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Gynecologic cancer].
    Sugiyama T; Takeuchi S; Fukagawa T
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):157-61. PubMed ID: 24743194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab and ovarian cancer.
    Sato S; Itamochi H
    Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
    Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
    J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma.
    Funakoshi Y; Hata N; Kuga D; Hatae R; Sangatsuda Y; Fujioka Y; Takigawa K; Mizoguchi M
    Pharmaceuticals (Basel); 2020 Dec; 13(12):. PubMed ID: 33339404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of bevacizumab for the treatment of glioblastoma.
    Yu Z; Zhao G; Zhang Z; Li Y; Chen Y; Wang N; Zhao Z; Xie G
    Exp Ther Med; 2016 Feb; 11(2):371-380. PubMed ID: 26893618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab: new drug. Metastatic colorectal cancer: good in theory, not in practice.
    Prescrire Int; 2006 Jun; 15(83):94-7. PubMed ID: 16764097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
    Manegold C
    Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial.
    Hovey EJ; Field KM; Rosenthal MA; Barnes EH; Cher L; Nowak AK; Wheeler H; Sawkins K; Livingstone A; Phal P; Goh C; Simes J;
    Neurooncol Pract; 2017 Sep; 4(3):171-181. PubMed ID: 31386014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bevacizumab for the treatment of glioblastoma.
    Gil-Gil MJ; Mesia C; Rey M; Bruna J
    Clin Med Insights Oncol; 2013; 7():123-35. PubMed ID: 23843722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial.
    Boisen MK; Holst CB; Consalvo N; Chinot OL; Johansen JS
    Oncotarget; 2018 Jan; 9(6):6752-6762. PubMed ID: 29467925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab for the treatment of recurrent glioblastoma.
    Chamberlain MC
    Clin Med Insights Oncol; 2011; 5():117-29. PubMed ID: 21603247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab.
    Wagle N; Nghiemphu L; Lai A; Pope W; Mischel PS; Cloughesy T
    Pharmgenomics Pers Med; 2010; 3():79-85. PubMed ID: 23226044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas.
    Shirai K; Siedow MR; Chakravarti A
    J Oncol; 2012; 2012():193436. PubMed ID: 21804824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contemporary Updates on Clinical Trials of Antiangiogenic Agents in the Treatment of Glioblastoma Multiforme.
    Kochar AS; Madhavan M; Manjila S; Scoco A; Belle VK; Geertman RT
    Asian J Neurosurg; 2018; 13(3):546-554. PubMed ID: 30283503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.